development and commercialization of diagnostic tests based on microRNA technology. The company was based in Rehovot, Israel, and was founded in 2000.
However, I must inform you that Rosetta Genomics Ltd was delisted from the NASDAQ stock exchange in May 2019 and is no longer actively traded. As of its delisting, the market capitalization of ROSG was not publicly available.
Prior to its delisting, Rosetta Genomics had developed a number of diagnostic tests for cancer and other diseases based on its proprietary microRNA technology. The company's products were designed to provide more accurate and personalized diagnoses for patients, helping to guide treatment decisions and improve outcomes.
In its later years, Rosetta Genomics faced financial difficulties and was forced to restructure its operations and reduce its workforce. Ultimately, the company was acquired by Genoptix, a subsidiary of Novartis, in 2019.
Overall, while Rosetta Genomics was a pioneering company in the field of microRNA-based diagnostics, its delisting and subsequent acquisition suggest that it faced significant challenges in bringing its products to market and achieving financial sustainability.
|
